Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002940 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002940: Completed Phase 2 study, sponsored by St. Jude Children's Research Hospital.
NCT00002940 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002940, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.
Interventions
- DRUG hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-10 |
| Est. Completion | 2002-03 |
| Phase | Phase 2 |
What the finished NCT00002940 record still lists
NCT00002940 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which hydroxyurea is the first listed.
NCT00002940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002940 about?
NCT00002940 is a clinical study titled "Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.
What is the current status of trial NCT00002940?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-10. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00002940?
The interventions under investigation include: hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00002940?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia